If the Phase 3 average holds around 28-29%, real-world results might land closer to 23-25%
Semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, has transformed treatment for type 2 diabetes and obesity
Reusing the reconstitution syringe for dosing
To be considered for tirzepatide treatment, clients should meet the following requirements: A Body Mass Index (BMI) of 30 kg/m or higher, qualifying as obesity, or a BMI of 27 kg/m or higher if accompanied by at least one weight-related health condition, such as Type 2 diabetes, hypertension, dyslipidemia (high cholesterol or triglycerides), obstructive sleep apnea, or nonalcoholic fatty liver disease (NAFLD)
The question is whether they are safe for a nursing infant whose entire nutritional world flows through your body